Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Influenza-associated morbidity and mortality has not decreased in the last decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza vaccine, a high-dose (HD) trivalent, inactivated influenza vaccine was developed. METHODS: A multicenter, randomized, double-blind controlled study was conducted to compare HD vaccine (which contains 60 microg of hemagglutinin per strain) with the licensed standard-dose (SD) vaccine (which contains 15 microg of hemagglutinin per strain) in adults > or = 65 years of age. RESULTS: HD vaccine was administered to 2575 subjects, and SD vaccine was administered to 1262 subjects. There was a statistically significant increase in the rates of seroconversion and mean hemagglutination inhibition titers at day 28 after vaccination among those who received HD vaccine, compared with those who received SD vaccine. Mean postvaccination titers for individuals who received HD vaccine were 116 for H1N1, 609 for H3N2, and 69 for B strain; for those who received SD vaccine, mean postvaccination titers were as 67 for H1N1, 333 for H3N2, and 52 for B strain. The HD vaccine met superiority criteria for both A strains, and the responses for B strain met non-inferiority criteria. Seroprotection rates were also higher for those who received HD vaccine than for those who received SD vaccine vaccine, for all strains. Local reactions were more frequent in individuals who received HD vaccine, but the reactions were mild to moderate. CONCLUSIONS: There was a statistically significant increase in the level of antibody response induced by HD influenza vaccine, compared with that induced by SD vaccine, without an attendant increase in the rate or severity of clinically relevant adverse reactions. These results suggest that the high-dose vaccine may provide improved protective benefits for older adults. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00391053 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of the above formulations show slightly higher immunogenicity in the elderly compared to the standard trivalent inactivated vaccine.”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [161]
In the citing paper
“for some populations, such as older adults, a higher dose might be beneficial, as has been shown for the influenza vaccine69,70.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [69]
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodInfluenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodAntibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064 · cited 2×
“vaccine effectiveness are generally lower in older adults [1, 4-6].”
BackgroundResultHobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,002 · cited 2×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundGovaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly
Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P., & Hak, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070844 · Cited by 656 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 543 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MAN
POTTER, C. W., & OXFORD, J. S. (1979) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a071545 · Cited by 452 · cited 1×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundVu, T., Farish, S., Jenkins, M., & Kelly, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00041-5 · Cited by 376 · cited 1×
“appears that efficacy is diminished in older age groups [18].”
BackgroundThe efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
Nichol, K. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00070-7 · Cited by 265
Cited by
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 2,076
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,632
“Fluad (aIIV3) was more effective against laboratory-confirmed influenza than unadjuvanted SD-IIV3 among adults aged ≥65 years (N = 227; 165 of whom received aIIV3 and 62 IIV3) in an analysis from a small single-season observational study (60).”
InfluentialA guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Factors That Influence the Immune Response to Vaccination
Zimmermann, P., & Curtis, N. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-18 · Cited by 939
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
DiazGranados, C. A., Dunning, A. J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., Pollak, R., Christoff, J., Earl, J., Landolfi, V., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315727 · Cited by 876
Self-citationHow sex and age affect immune responses, susceptibility to infections, and response to vaccination
Giefing‐Kröll, C., Berger, P., Lepperdinger, G., & Grubeck‐Loebenstein, B. (2015) · Aging Cell · doi:10.1111/acel.12326 · Cited by 761
“…effectiveness for influenza (Wang et al., 2002; Cook et al., 2006; Hui et al., 2006; Couch et al., 2007; Nichol et al., 2007; Engler et al., 2008; Falsey et al., 2009; Klein et al., 2010c, 2012; Talaat et al., 2010; Khurana et al., 2012; Furman et al., 2014), pneumococcal polysaccharide…”
BackgroundGrohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
“These criteria were met for influenza A(H1N1) and influenza A(H3N2) virus antigens, but not for the influenza B virus antigen (for which criteria for noninferiority were met) (181,183).”
BackgroundSex-based differences in immune function and responses to vaccination
Klein, S. L., Marriott, I., & Fish, E. N. (2015) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/tru167 · Cited by 542
Udell, J. A., Zawi, R., Bhatt, D. L., Keshtkar-Jahromi, M., Gaughran, F., Phrommintikul, A., Ciszewski, A., Vakili, H., Hoffman, E. B., Farkouh, M. E., et al. (2013) · JAMA · doi:10.1001/jama.2013.279206 · Cited by 516
Aging of the immune system: Focus on inflammation and vaccination
Pinti, M., Appay, V., Campisi, J., Frasca, D., Fülöp, T., Sauce, D., Larbi, A., Weinberger, B., & Cossarizza, A. (2016) · European Journal of Immunology · doi:10.1002/eji.201546178 · Cited by 439
Vaccination in the elderly: The challenge of immune changes with aging
Ciabattini, A., Nardini, C., Santoro, F., Garagnani, P., Franceschi, C., & Medaglini, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.010 · Cited by 411
Grohskopf, L. A., Shay, D. K., Shimabukuro, T. T., Sokolow, L. Z., Keitel, W. A., Bresee, J., & Cox, N. J. (2013) · PubMed · Cited by 567
Grohskopf, L. A., Alyanak, E., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2019) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6803a1 · Cited by 393
Traditional and New Influenza Vaccines
Wong, S.-S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 372
“Given the poor performance of TIVs in the elderly, Fluzone HighDose, a new formulation of TIV that contains four times the standard dose of HA, was approved for use in the elderly in the United States in 2010.”
BackgroundInfluentialGrohskopf, L. A., Alyanak, E., Ferdinands, J. M., Broder, K. R., Blanton, L. H., Talbot, H. K., & Fry, A. M. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7005a1 · Cited by 360
Grohskopf, L. A., Alyanak, E., Broder, K. R., Blanton, L. H., Fry, A. M., Jernigan, D. B., & Atmar, R. L. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6908a1 · Cited by 332
“A meta-analysis reported that HD-IIV3 provided better protection than SD-IIV3 against ILI (relative VE = 19.5%; 95% CI: 8.6%–29.0%); all-cause hospitalizations (relative VE = 9.1%; 95% CI: 2.4%–15.3%); and hospitalizations due to influenza (relative VE = 17.8%; 95% CI: 8.1%–26.5%), pneumonia (relative VE = 24.3%; 95%…”
BackgroundInfluentialWatson, D. S., Endsley, A. N., & Huang, L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.070 · Cited by 322
“Antigen dose is another important consideration that is determined by the age, nutritional status, and immune status of the target population [39, 40]; for example, increased doses have been found to generate significantly higher antibody responses to a trivalent inactivated influenza vaccine in adults over 65 years o…”
BackgroundGrohskopf, L. A., Blanton, L. H., Ferdinands, J. M., Chung, J. R., Broder, K. R., Talbot, H. K., Morgan, R. L., & Fry, A. M. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7101a1 · Cited by 320
“In comparative safety studies, certain injection site and systemic reactions were observed more frequently in older persons vaccinated with HD-IIV3 and aIIV3 compared with nonadjuvanted SD-IIV3 (86,87).”
BackgroundInfluentialThe Confluence of Sex Hormones and Aging on Immunity
Gubbels Bupp, M. R., Potluri, T., Fink, A. L., & Klein, S. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01269 · Cited by 277
“For example, among individuals 65+ years of age, hemagglutinin inhibition antibody titers to both the standard and high dose seasonal trivalent inactivated influenza (TIV) vaccine are significantly higher in aged females when compared with males (174).”
BackgroundTreanor, J. J., Talbot, H. K., Ohmit, S. E., Coleman, L. A., Thompson, M. G., Cheng, P.-Y., Petrie, J. G., Lofthus, G., Meece, J. K., Williams, J. V., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis574 · Cited by 258
Self-citationPlennevaux, E., Sheldon, E., Blatter, M., Reeves-Hoché, M.-K., & Denis, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62026-2 · Cited by 245
Natori, Y., Shiotsuka, M., Slomovic, J., Hoschler, K., Ferreira, V., Ashton, P., Rotstein, C., Lilly, L., Schiff, J., Singer, L., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1082 · Cited by 183
“4% greater with HD vaccine compared to SD vaccine in persons aged ≥65 years [16].”
Izurieta, H. S., Thadani, N., Shay, D. K., Lu, Y., Maurer, A., Foppa, I. M., Franks, R., Pratt, D., Forshee, R. A., MaCurdy, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71087-4 · Cited by 181
Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly
Pereira, B., Xu, X.-N., & Akbar, A. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583019 · Cited by 178
“Alternatively, the use of high-dose influenza vaccines in individuals over 65 years has also been shown to induce higher antibody titers and seroprotection rates compared to standarddose vaccine (91), leading to their approval for clinical use in person aged 65 and older (92).”
BackgroundWilkinson, K., Wei, Y., Szwajcer, A., Rabbani, R., Zarychanski, R., Abou-Setta, A. M., & Mahmud, S. M. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.092 · Cited by 173
Influenza vaccination in the elderly
Smetana, J., Chlibek, R., Shaw, J., Splino, M., & Prymula, R. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1343226 · Cited by 168
“Boosting the vaccine dose 4-fold may confer a concomitant increase in antigenic presentation.(103,104,105,106) However, as noted previously, perhaps a better hallmark of immunogenicity and durability of protection in the elderly is the T lymphocyte response measured by ex vivo cytokine and granzyme B production, not a…”
BackgroundThe evolution of greater humoral immunity in females than males: implications for vaccine efficacy
Fink, A. L., & Klein, S. L. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.03.010 · Cited by 166
Barberis, I., Myles, P. R., Ault, S. K., Bragazzi, N. L., & Martini, M. (2016) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2016.57.3.642 · Cited by 170
“For this reason, in 2009 the Advisory Committee on Immunization Practices (ACIP) recommended and authorized the use of high-dose Fluzone, a new formulation containing a 4-fold higher HA dose than the traditional trivalent vaccine [43].”
BackgroundTaylor, D. N., Treanor, J. J., Strout, C., Johnson, C., Fitzgerald, T., Kavita, U., Ozer, K., Tussey, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.001 · Cited by 160
Self-citationSex and Gender Impact Immune Responses to Vaccines Among the Elderly
Fink, A. L., & Klein, S. L. (2015) · Physiology · doi:10.1152/physiol.00035.2015 · Cited by 156
Influenza vaccine responses in older adults
McElhaney, J. E. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.10.008 · Cited by 155
Age‐associated elevation in TLR5 leads to increased inflammatory responses in the elderly
Qian, F., Wang, X., Zhang, L., Chen, S., Piecychna, M., Allore, H., Bockenstedt, L., Malawista, S., Bucala, R., Shaw, A. C., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2011.00759.x · Cited by 154
“…in elderly, F. Qian et al. ª 2011 The Authors Aging Cell ª 2011 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland 107 vaccination reported previously for subjects >65 years (Falsey et al., 2009), suggesting enhanced efficiency through targeting TLR5 (Taylor et al., 2011).”
BackgroundSex-based Biology and the Rational Design of Influenza Vaccination Strategies
Klein, S. L., & Pekosz, A. S. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu066 · Cited by 144
Song, J. Y., Cheong, H. J., Hwang, I. S., Choi, W. S., Jo, Y. M., Park, D. W., Cho, G. J., Hwang, T. G., & Kim, W. J. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.067 · Cited by 147
Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals
Tebas, P., Frank, I., Lewis, M. G., Quinn, J., Zifchak, L. M., Thomas, A., Kenney, T. J., Kappes, R., Wagner, W., Maffei, K., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833c6d5c · Cited by 141
“What strategies can be used to improve these immunological responses? Higher dose of the antigen has been associated with higher antibody titers in many studies and can improve the immunogenicity of the influenza vaccine in poorly responsive populations such as the elderly [35].”
BackgroundInactivated influenza vaccines
Fiore, A. E., Bridges, C. B., Katz, J. M., & Cox, N. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00026-4 · Cited by 147
Aging and influenza vaccine-induced immunity
Dugan, H. L., Henry, C., & Wilson, P. C. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103998 · Cited by 142
Mulligan, M. J., Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., et al. (2014) · JAMA · doi:10.1001/jama.2014.12854 · Cited by 133
“(%) [95% CI]a 81 (82) [73-89] 72 (73) [64-82] 70 (71) [61-79] 65 (66) [56-76] 40 (40) [31-51] 13 (13) [7-21] 21 (21) [14-31]”
InfluentialExploiting Mucosal Immunity for Antiviral Vaccines
Iwasaki, A. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112315 · Cited by 146
Lambert, N. D., Ovsyannikova, I. G., Pankratz, V. S., Jacobson, R. M., & Poland, G. A. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.61 · Cited by 127
Dhakal, S., & Klein, S. L. (2019) · Journal of Virology · doi:10.1128/jvi.00797-19 · Cited by 134
DiazGranados, C. A., Dunning, A. J., Jordanov, E., Landolfi, V. A., Denis, M., & Talbot, H. K. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.013 · Cited by 127
Reed, C., Kim, I. K., Singleton, J. A., Chaves, S. S., Flannery, B. L., Finelli, L., Fry, A. M., Burns, E. M., Gargiullo, P. M., Jernigan, D. B., et al. (2014) · PubMed · Cited by 120
Izikson, R., Brune, D., Bolduc, J.-S., Bourron, P., Fournier, M., Moore, T. M., Pandey, A., Perez, L., Sater, N., Shrestha, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00557-9 · Cited by 112
“…line with previous descriptions of the reactogenicity, safety, and immunogenicity of high-dose influenza vaccine in adults aged 65 years and older 40,41 or after two 100 µg doses of mRNA-1273 in adults aged 55 years and older, 42,43 and are in line with safety descriptions in the QIV-HD and…”
Greenberg, D. P., Robertson, C. A., Noss, M. J., Blatter, M. M., Biedenbender, R., & Decker, M. D. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.074 · Cited by 118
Shay, D. K., Chillarige, Y., Kelman, J. A., Forshee, R. A., Foppa, I., Wernecke, M., Lu, Y., Ferdinands, J. M., Iyengar, A., Fry, A. M., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw641 · Cited by 108
Utility of Influenza Vaccination for Oncology Patients
Pollyea, D. A., Brown, J. M. Y., & Horning, S. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6908 · Cited by 104
Antrobus, R., Berthoud, T. K., Mullarkey, C. E., Höschler, K., Coughlan, L., Zambon, M. C. F. A., Hill, A. V. S., & Gilbert, S. C. (2013) · Molecular Therapy · doi:10.1038/mt.2013.162 · Cited by 114
Immunosenescence and Novel Vaccination Strategies for the Elderly
Dorrington, M. G., & Bowdish, D. M. E. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00171 · Cited by 115
Dunning, A. J., DiazGranados, C. A., Voloshen, T., Hu, B. T., Landolfi, V. A., & Talbot, H. K. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00604-15 · Cited by 104
“Candidate novel vaccines for the elderly have elicited higher HAI titers (4, 9, 10), in some cases approaching levels comparable to those seen in younger adults (11), and improvements in efficacy and effectiveness relative to standard inactivated trivalent vaccine have been seen (4, 5, 12).”
ResultTreanor, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1512870 · Cited by 105
Self-citationThree Sudden Cardiac Deaths Associated With Lyme Carditis—United States, November 2012 to July 2013
(2014) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000284 · Cited by 98
Factors affecting immune responses to the influenza vaccine
Castrucci, M. R. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1338547 · Cited by 110
“Among older adults who received the high-dose TIV, Falsey et al.64 documented higher antibody responses against each of the 3 influenza antigens in females compared with males.”
BackgroundCaldera, F., Hillman, L., Saha, S., Wald, A. M., Grimes, I. C., Zhang, Y., Sharpe, A. R., Reichelderfer, M., & Hayney, M. S. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz164 · Cited by 103
Tsang, P., Gorse, G. J., Strout, C. B., Sperling, M., Greenberg, D. P., Ozol-Godfrey, A., DiazGranados, C., & Landolfi, V. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.09.074 · Cited by 91
Self-citationDiazGranados, C. A., Dunning, A. J., Robertson, C. A., Talbot, H. K., Landolfi, V. A., & Greenberg, D. P. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.003 · Cited by 96
Talbot, H. K., Rock, M. T., Johnson, C., Tussey, L., Kavita, U., Shanker, A., SHAW, A. R., & Taylor, D. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014442 · Cited by 97
“[10] a high dose TIV with a 4-fold increase in HA content was only able to induce a 1.”
BackgroundDamme, P. V., Arnou, R., Kafeja, F., Fiquet, A., Richard, P., Thomas, S., Meghlaoui, G., Samson, S., & Ledesma, E. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-134 · Cited by 93
Sex Differences in Older Adults' Immune Responses to Seasonal Influenza Vaccination
Voigt, E. A., Ovsyannikova, I. G., Kennedy, R. B., Grill, D. E., Goergen, K. M., Schaid, D. J., & Poland, G. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00180 · Cited by 90
“Previous studies investigating sex differences in seasonal influenza vaccine responses have largely examined antibody titers, reaching no clear consensus (8, 9, 44, 60, 61).”
BackgroundSullivan, S. G., Price, O. H., & Regan, A. K. (2019) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135519826481 · Cited by 92
Age and testosterone mediate influenza pathogenesis in male mice
Steeg, L. G. V., Vermillion, M. S., Hall, O. J., Alam, O., McFarland, R., Chen, H., Zirkin, B. R., & Klein, S. L. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00352.2016 · Cited by 83
GiaQuinta, S., Michaels, M. G., McCullers, J. A., Wang, L., Fonnesbeck, C., O’Shea, A., Green, M., & Halasa, N. (2014) · Pediatric Transplantation · doi:10.1111/petr.12419 · Cited by 78
Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection
Merani, S., Pawelec, G., Kuchel, G. A., & McElhaney, J. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00784 · Cited by 74
“Dosage Studies comparing dosage of trivalent inactivated influenza virus vaccines in older adults have found that people who received high dose vaccinations had significantly higher antibody titers for all three strains (to varying degrees) than those who received standard dose vaccinations (179, 180).”
BackgroundNg, T. W. Y., Cowling, B. J., Gao, H., & Thompson, M. G. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy720 · Cited by 82
Mohanty, S., Joshi, S. R., Ueda, I., Wilson, J., Blevins, T. P., Siconolfi, B., Meng, H., Devine, L., Raddassi, K., Tsang, S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu573 · Cited by 67
“It will be of interest to determine whether the impaired activation of IL-6 and TNF-α expression and increase in IL-10 expression are affected by high-dose [34, 35] or adjuvanted [36] influenza vaccines that are associated with improved HAI titers in older adults.”
BackgroundThe combination of artificial intelligence and systems biology for intelligent vaccine design
Russo, G., Reche, P., Pennisi, M., & Pappalardo, F. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1791076 · Cited by 71
Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected Persons
McKittrick, N. D., Frank, I., Jacobson, J. M., White, C. J., Kim, D., Kappes, R., DiGiorgio, C., Kenney, T., Boyer, J., & Tebas, P. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-1-201301010-00005 · Cited by 70
Protection against Lethal Influenza with a Viral Mimic
Baker, S. F., Guo, H., Albrecht, R. A., García‐Sastre, A., Topham, D. J., & Martínez‐Sobrido, L. (2013) · Journal of Virology · doi:10.1128/jvi.01081-13 · Cited by 69
“Thus, perhaps it was not surprising that recent meta-analysis of the two Food and Drug Administration (FDA)-approved influenza vaccines (trivalent inactivated virus, TIV; live-attenuated influenza virus, LAIV) used to protect against influenza disease revealed a mere 35% effectiveness (4).”
BackgroundInfluentialAdversomics: a new paradigm for vaccine safety and design
Whitaker, J. A., Ovsyannikova, I. G., & Poland, G. A. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1038249 · Cited by 76
“With regard to influenza vaccine, systemic symptoms among older individuals (‡65 years old) were more frequent following vaccination with high-dose trivalent, inactivated influenza vaccine (180 mcg of HA antigen) compared with a standard dose of 45 mcg [120].”
Halasa, N., Savani, B. N., Asokan, I., Kassim, A. A., Simons, R. M., Summers, C., Bourgeois, J., Clifton, C., Vaughan, L. A., Lucid, C., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.12.003 · Cited by 69
“These results are similar to the 3 previous studies performed in the elderly population in which higher rates of injection-site reactions were reported in HD TIV recipients [40,42,45] and in our parallel study conducted in pediatric solid-organ transplant recipients [46].”
BackgroundResultPica, N., Langlois, R. A., Krammer, F., Margine, I., & Palese, P. (2012) · Journal of Virology · doi:10.1128/jvi.01131-12 · Cited by 73
“Clinical studies comparing standard-dose and high-dose formulations demonstrated statistically higher HI titers in response to highdose vaccination (14, 17, 25, 38).”
BackgroundResta, C. D., Ferrari, D., Viganò, M., Moro, M., Sabetta, E., Minerva, M., Ambrosio, A. G., Locatelli, M., & Tomaiuolo, R. (2021) · Vaccines · doi:10.3390/vaccines9050522 · Cited by 70
“In addition, females show a better response to vaccination [18,19], however, side effects are significantly more frequent [20].”
BackgroundChen, W. H., Cross, A. S., Edelman, R., Sztein, M. B., Blackwelder, W. C., & Pasetti, M. F. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.017 · Cited by 67
Arriola, C. S., Anderson, E. J., Baumbach, J., Bennett, N. M., Bohm, S. R., Hill, M. B., Lindegren, M. L., Lung, K. L., Meek, J. I., Mermel, E., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv200 · Cited by 68
“Nonetheless, new vaccines with improved vaccine effectiveness, such as adjuvanted influenza vaccine [30] or a high-dose vaccine [28, 29], and other strategies such as early and aggressive antiviral treatment [17, 38, 39, 43] are needed to reduce morbidity and mortality due to influenza virus infection in vulnerable po…”
BackgroundDevices and formulations for pulmonary vaccination
Tonnis, W. F., Lexmond, A. J., Frijlink, H. W., de Boer, A. H., & Hinrichs, W. L. J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.810622 · Cited by 67
“The limited immunogenicity after injection of some vaccines [1,2].”
BackgroundRichardson, D. M., Medvedeva, E. L., Roberts, C. B., & Linkin, D. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ261 · Cited by 68
“Our findings are not directly comparable to the results of earlier randomized studies, which have demonstrated superior immunogenicity [13, 14, 29, 30] and efficacy in preventing influenza [14] in adults ≥65 years of age who received HD vaccine relative to those vaccinated with SD vaccine.”
Pilkinton, M. A., Nicholas, K. J., Warren, C. M., Smith, R. M., Yoder, S. M., Talbot, H. K., & Kalams, S. A. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.059 · Cited by 64
T Follicular Helper Cells and B Cell Dysfunction in Aging and HIV-1 Infection
Pallikkuth, S., de Armas, L. R., Rinaldi, S., & Pahwa, S. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01380 · Cited by 68
“Sex differences in HAI antibody titers to either the standard-dose or high-dose influenza vaccine are apparent, in which antibody responses are higher in older females than in males (108, 109).”
BackgroundLang, P. O., Govind, S., Mitchell, W. A., Siegrist, C., & Aspinall, R. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.09.005 · Cited by 73
“New formulations already tested on older individuals include increasing the TIV dosage (60 g versus 15 g of HA) (Cate et al., 2009; Falsey et al., 2009); changes in the type of vaccine (live attenuated vaccines (LAVs) (De Villiers et al., 2009); virosomal vaccines (Huckriede et al., 2005); and…”
BackgroundCunningham, A. L., McIntyre, P. B., Subbarao, K., Booy, R., & Levin, M. J. (2021) · BMJ · doi:10.1136/bmj.n188 · Cited by 75
Intanza®: a new intradermal vaccine for seasonal influenza
Atmar, R. L., Patel, S. M., & Keitel, W. A. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.134 · Cited by 59
Age-related changes in the immune system and challenges for the development of age-specific vaccines
Doherty, M. T., Weinberger, B., Didierlaurent, A. M., & Lambert, P. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2477300 · Cited by 75
“Randomised trials in older adults have shown that high-dose influenza vaccines elicit higher antibody titres and higher seroconversion rates than standard-dose vaccines (Figure 2) [72–74].”
Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors
Chit, A., Roïz, J., Briquet, B., & Greenberg, D. P. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.10.079 · Cited by 63
Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults
Chi, R., Rock, M. T., & Neuzil, K. M. (2010) · Clinical Infectious Diseases · doi:10.1086/652144 · Cited by 60
Fluzone® High-Dose Influenza Vaccine
Robertson, C. A., DiazGranados, C. A., Decker, M. D., Chit, A., Mercer, M., & Greenberg, D. P. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1254044 · Cited by 66
A systematic review of the health economic consequences of quadrivalent influenza vaccination
de Boer, P. T., van Maanen, B. M., Damm, O., Ultsch, B., Dolk, F. C. K., Crépey, P., Pitman, R., Wilschut, J., & Postma, M. J. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1343145 · Cited by 60
“…newly developed influenza vaccines, like high-dose vaccines and adjuvanted vaccines, have been shown to have improved immunogenicity and may, potentially, induce better cross-protection as compared with standard vaccines [69,70], their efficacy toward unmatched viruses remain to be analyzed.”
BackgroundTadount, F., Doyon-Plourde, P., Rafferty, E., MacDonald, S. E., Sadarangani, M., & Quach, C. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.10.091 · Cited by 56
Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population
Stephens, L. M., & Varga, S. M. (2021) · Vaccines · doi:10.3390/vaccines9060624 · Cited by 55
Inactivated Influenza Vaccines: Recent Progress and Implications for the Elderly
Parodi, V., de Florentiis, D., Martini, M., & Ansaldi, F. (2011) · Drugs & Aging · doi:10.2165/11586770-000000000-00000 · Cited by 56
“A safety and tolerability evaluation in adults aged ‡65 years showed that solicited injection site reactions and systemic adverse events were more frequent after vaccination with the high-dose formulation compared with the standard-dose split vaccine, but typically were mild and transient.([97,100,105]) In the largest…”
BackgroundResultTalbot, H. K. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.07.005 · Cited by 54
“Early trials showed a significant antibody increase to influenza A (but not influenza B).(42) A large phase IIIb/IV study showed a relative effectiveness of 24% for the high-dose versus the standard-dose influenza vaccine.”
Background(2014) · American Journal of Transplantation · doi:10.1111/ajt.12659 · Cited by 54
Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?
Hazeldine, J., & Lord, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573662 · Cited by 67
Hayney, M. S., Coe, C. L., Muller, D., Obasi, C. N., Backonja, U., Ewers, T., & Barrett, B. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26661 · Cited by 51
Hakim, H., Allison, K., de Velde, L.-A. V., Tang, L., Sun, Y., Flynn, P. M., & McCullers, J. A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.053 · Cited by 52
miR-181a-regulated pathways in T-cell differentiation and aging
Kim, C., Ye, Z., Weyand, C. M., & Goronzy, J. J. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00240-1 · Cited by 58
Scheifele, D. W., McNeil, S., Ward, B. J., Dionne, M., Cooper, C., Coleman, B. L., Loeb, M. B., Rubinstein, E., McElhaney, J. E., Hatchette, T. F., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25580 · Cited by 50
Nace, D. A., Lin, C. J., Ross, T. M., Saracco, S., Churilla, R. M., & Zimmerman, R. K. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu622 · Cited by 51
“Prior studies evaluating HD IIV were conducted in healthy or medically stable community-dwelling older adults and showed an enhanced immunologic response with no major safety concerns [11, 12, 30].”
The life cycle of a T cell after vaccination – where does immune ageing strike?
Kim, C., Fang, F., Weyand, C. M., & Goronzy, J. J. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12829 · Cited by 49
Johansen, N. D., Modin, D., Pardo‐Seco, J., Rodrı́guez-Tenreiro, C., Loiacono, M. M., Harris, R. C., Dufournet, M., van Aalst, R., Chit, A., Larsen, C. S., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01742-8 · Cited by 53
Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine
Sullivan, S. J., Jacobson, R. M., & Poland, G. A. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.117 · Cited by 54
Metadata
- Authors
- Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J.
- Affiliations
- University of Rochester Medicine (US)
- St. Louis VA Medical Center (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-15
- Volume
- 200
- Issue
- 2
- Pages
- 172-180
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2164949714
- Cited by
- 388
- References
- 22
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 12 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 25 · 2019: 33 · 2018: 25 · 2017: 22 · 2016: 23 · 2015: 25 · 2014: 32 · 2013: 34 · 2012: 24
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- high-dose influenza vaccine, standard-dose influenza vaccine, immunogenicity, older adults, seroconversion, hemagglutination inhibition titers, trivalent inactivated influenza vaccine, vaccine dose comparison, local adverse reactions, seroprotection rate
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Viral, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.